Wrap Text
Appointment of Dr Muhadditha Yahya Al Hashimi as an independent non-executive director
Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic” or “the Company”)
APPOINTMENT OF DR MUHADDITHA YAHYA AL HASHIMI AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR
31 October 2017
Mediclinic announces that Dr Muhadditha Yahya Al Hashimi will join its Board as an Independent Non-
Executive Director with effect from 1 November 2017.
Dr Edwin Hertzog, Chairman of Mediclinic, commented:
“Dr Al Hashimi has extensive experience and knowledge of the healthcare and higher education sectors
in the UAE, together with strategic and tactical expertise in operations and fiscal management. The
Board is delighted to welcome Dr Al Hashimi as a Non-Executive Director of the Company and we look
forward to her contribution.”
Dr Al Hashimi is also a member of the Board of Trustees and the Audit and Compliance Committee of
the University of Sharjah, a member of the Board of Trustees of the UAE Nursing and Midwifery Council
and of the UAE Genetics Diseases Association, and the Campus Director of Higher Colleges of
Technology Sharjah Women’s College in the UAE.
Prior to her current positions, Dr Al Hashimi was the Executive Dean of the Faculty of Health Sciences,
Higher Colleges of Technology; Acting Deputy Vice Chancellor – Academic Affairs at the Higher
Colleges of Technology; Chief Executive Officer of the Mohammed Bin Rashid Al Maktoum Academic
Medical Center in Dubai; Deputy Chief Executive Officer of Tatweer, LLC; Chief Executive Officer of
Dubai Healthcare City (both members of Dubai Holding); and Director of Education of the Harvard
Medical School Dubai Centre.
Dr Al Hashimi obtained a Doctorate in Public Health (University of Texas, USA), a Master’s Degree in
Clinical Laboratory Sciences (University of Minnesota, USA) and a Bachelor’s Degree in Medical
Technology (University of Minnesota, USA).
There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing
Authority's Listing Rules in respect of this appointment. Dr Al Hashimi’s fees will amount to £60,000 per
annum, in-line with current independent non-executive directors.
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South
Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the
quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-
based private healthcare group.
Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in
total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1
700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700
inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international private
healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986,
with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai).
The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in
South Africa and the NSX in Namibia.
For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby / Caroline Emmet
+44 (0)20 7954 9600
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard / Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, United Kingdom, EC2V 7NQ
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 31/10/2017 04:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
